These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36292610)

  • 41. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
    Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z
    Front Immunol; 2022; 13():925618. PubMed ID: 35898502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
    Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
    Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.
    Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K
    Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
    Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
    Front Genet; 2022; 13():969856. PubMed ID: 36226187
    [No Abstract]   [Full Text] [Related]  

  • 47. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
    Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
    Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An immune scores-based nomogram for predicting overall survival in patients with clear cell renal cell carcinoma.
    Wu Z; Ouyang C; Peng L
    Medicine (Baltimore); 2020 Aug; 99(34):e21693. PubMed ID: 32846785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
    Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
    BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.
    Sun P; Xu H; Zhu K; Li M; Han R; Shen J; Xia X; Chen X; Fei G; Zhou S; Wang R
    Front Genet; 2022; 13():1061382. PubMed ID: 36531222
    [No Abstract]   [Full Text] [Related]  

  • 59. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 60. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.
    Ding L; Li W; Tu J; Cao Z; Li J; Cao H; Liang J; Liang Y; Yu Q; Li G
    Front Immunol; 2022; 13():989156. PubMed ID: 36177029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.